Skip to main content

Table 2 Systemic Treatment, Surgery, Radiation and Utilization Post-Recurrence

From: BRCA testing, treatment patterns and survival in platinum-sensitive recurrent ovarian cancer – an observational cohort study

Treatment Type

BRCAm

BRCAwt

Untested

n = 15

% or Range

p-Value

n = 25

% or Range

p-Value*

n = 128

% or Range

p-Value**

Systemic Treatment

 Systemic treatment received, n

14

93.3 %

ref

23

92.0 %

0.876

101

78.9 %

0.138

 Missing/unknown, n

1

6.7 %

-

1

4.0 %

-

16

12.5 %

-

 Median number of treatment lines (IQR)

4 (2–4)

0–6

ref

3 (1–5)

0–11

0.832

2 (1–3)

0–6

0.001

 Platinum-containing regimen post-recurrence, n

13

86.7 %

ref

19

76.0 %

0.404

86

67.2 %

0.098

Cytoreductive Surgery

 Secondary cytoreductive surgery, n

7

46.7 %

ref

13

52.0 %

0.744

52

40.6 %

0.655

 Missing/unknown, n

0

0.0 %

-

0

0.0 %

-

5

3.9 %

-

Median months to cytoreductive surgery from recurrence (IQR)

8.8 (1.5–38.8)

0–93.5

ref

0.8 (−0.4–3.4)

−0.5–11.7

0.067

0.4 (−0.1–3.4)

−0.8–71.9

0.064

Radiation Therapy

 Radiation therapy, n

7

46.7 %

ref

9

36.0 %

0.506

25

19.5 %

0.027

 Missing/unknown, n

0

0.0 %

-

0

0.0 %

-

5

3.9 %

-

Median months to radiation therapy from recurrence (IQR)

15.8 (7.2–21.9)

1.7–29.4

ref

19.7 (17.0–26.5)

11.7–34.5

0.333

3.5 (1.3–11.7)

0.1–81.5

0.109

No Treatment (Surgery, Radiation, Systemic), n

0

0.0 %

-

0

0.0 %

-

3

2.3 %

-

Total Unknown/Missing (Surgery, Radiation, Systemic), n

0

0.0 %

-

0

0.0 %

-

5

3.9 %

-

  1. *BRCAm vs. BRCAwt;**BRCAm vs. Untested